- CCMP Capital faced a key-man crisis after co-founder and former CEO Steve Murray left for health-related reasons and died in March 2015.
- His departure triggered key-man provisions on a $3.6 billion fund, forcing LP votes to restore the firm’s authority to make new investments.
- Opaque disclosure about Murray’s condition contrasted with private candor to select LPs, raising governance and transparency concerns.
- Under new CEO Greg Brenneman, CCMP (now CCMP Growth) stabilized LP support, raised new funds, and shifted toward growth-focused middle-market investing.
Read More
The death of Steve Murray placed CCMP at a critical inflection point: not only was a founder and face of the firm lost, but due to his role as co-CEO under whose tenure significant deal-flow and fundraising were achieved, the firm’s operational and governance structures were stress-tested. The triggering of key-man provisions in the then-new $3.6 billion fund meant LPs had formal rights to limit or stop new investments, forcing CCMP to demonstrate sufficient depth and continuity beyond Murray alone. [3]
CCMP’s use of opaque language (“health-related” leave) in written disclosures contrasted with more candid verbal conversations with certain LPs. That discrepancy raises governance and transparency risks typical in private equity: failure to appropriately manage stakeholder communication can impair LP trust, affecting future fundraises. While the broader partnership’s involvement—including Greg Brenneman’s elevation and reliance on the rest of the investment committee—provided a clear path to continuity, the timeline and manner of disclosure likely placed pressure on internal decision-making and LP perceptions. [3]
Strategically, CCMP was forced to lean heavily on LP affirmations (via votes) to reinstate the fund’s investment mandate. The fact that the fund was ~40% committed, and that LPs had recently committed capital trusting the broader team—not just Murray—worked in the firm’s favor. However, had LPs withheld sanction, CCMP might have faced significant reputational and financial risk, including capital return or altered deal execution. [3]
Post-Murray era developments indicate that CCMP (later rebranded CCMP Growth) succeeded in raising new funds (such as CCMP IV, with a target of USD 500 million) showing regeneration of LP support and a strategy shift toward growth-oriented, middle-market platforms. [1][6] This suggests that the firm managed not only through a crisis of governance but also through strategic evolution on fund focus and leadership. But the legacy of the Murray incident likely imposes lessons around disclosure, key-man dependency, and LP governance.
Supporting Notes
- Steve Murray left CCMP Capital in February 2015 due to “health-related” issues; he died on March 12, 2015, age 52. [2][3]
- CCMP was alerted in December 2014 to Murray’s possible substance abuse; in January 2015 he was placed on a 60-day medical leave. [3]
- Murray’s departure triggered key-man provisions on CCMP’s $3.6 billion fund (closed just the previous September). [3]
- The fund was about 40 % committed when the key-man clauses were triggered; LPs had committed to the broader team in recent deals. [3]
- Greg Brenneman, formerly chairman, took over as CEO following Murray’s departure and after Murray’s death.[3]
- Since 2022 the firm (as CCMP Growth) has raised CCMP IV in excess of a $500 million target and invested in four companies with strong growth metrics (16 % revenue growth, 21 % EBITDA growth in 2023). [1][6]
Sources
- fortune.com (Fortune) — March 13, 2015
- [2] www.bloomberg.com (Bloomberg) — March 13, 2015
- [3] fortune.com (Fortune) — March 18, 2015
- [1] www.businesswire.com (Business Wire) — July 17, 2024
- [6] www.businesswire.com (Valdosta Daily Times (via Business Wire)) — July 17, 2024
- [12] en.wikipedia.org (Wikipedia) — n.d.
